Literature DB >> 15052509

The AMSP drug safety program: methods and global results.

R Grohmann1, R R Engel, E Rüther, H Hippius.   

Abstract

The AMSP (Arzneimittelsicherheit in der Psychiatry) study is a drug safety program that ensures the continuous assessment of severe adverse drug reactions (ADR) in psychiatric inpatients under the natural conditions of routine clinical treatment. It developed out of the preceding drug surveillance study AMUP (Arzneimittelüberwachung in der Psychiatrie). Currently 35 hospitals participate in the study. This paper describes the methods of the AMSP, gives detailed definitions of ADRs assessed to be "severe," and discusses the implications of these definitions and the methodological approach for evaluating the AMSP data. In addition, some overall data compiled on ADR rates from 1993 to 2000 are given.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15052509     DOI: 10.1055/s-2004-815505

Source DB:  PubMed          Journal:  Pharmacopsychiatry        ISSN: 0176-3679            Impact factor:   5.788


  25 in total

1.  Are clozapine blood dyscrasias associated with concomitant medications?

Authors:  Tammie Lee Demler; Eileen Trigoboff
Journal:  Innov Clin Neurosci       Date:  2011-04

2.  Neuroleptic malignant syndrome: evaluation of drug safety data from the AMSP program during 1993-2015.

Authors:  Michael Schneider; Johannes Regente; Timo Greiner; Stephanie Lensky; Stefan Bleich; Sermin Toto; Renate Grohmann; Susanne Stübner; Martin Heinze
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2018-11-30       Impact factor: 5.270

3.  [Adverse drugs reactions: diagnosis and assessment].

Authors:  P A Thürmann
Journal:  Pathologe       Date:  2006-02       Impact factor: 1.011

4.  Principle standards and problems regarding proof of efficacy in clinical psychopharmacology.

Authors:  Hans-Jürgen Möller; Karl Broich
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2010-02       Impact factor: 5.270

5.  Pharmacotherapy of psychiatric inpatients with adjustment disorder: current status and changes between 2000 and 2016.

Authors:  Timo Greiner; Beatrice Haack; Sermin Toto; Stefan Bleich; Renate Grohmann; Frank Faltraco; Martin Heinze; Michael Schneider
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2019-08-22       Impact factor: 5.270

6.  Severe parkinsonism under treatment with antipsychotic drugs.

Authors:  Katrin Druschky; Stefan Bleich; Renate Grohmann; Rolf R Engel; Sermin Toto; Alexandra Neyazi; Barbara Däubl; Susanne Stübner
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2019-08-23       Impact factor: 5.270

7.  Flupentixol use and adverse reactions in comparison with other common first- and second-generation antipsychotics: data from the AMSP study.

Authors:  R Grohmann; R R Engel; H-J Möller; E Rüther; J W van der Velden; S Stübner
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2013-07-09       Impact factor: 5.270

8.  Pharmacotherapy of anxiety disorders in German-speaking countries: current status and changes between 1994 and 2011.

Authors:  Anna K Holl; Renate Grohmann; Martin Letmaier; Annamaria Painold; Sabrina Mörkl; Sermin Toto; Siegfried Kasper
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2014-08-20       Impact factor: 5.270

9.  Comparative performance of two drug interaction screening programmes analysing a cross-sectional prescription dataset of 84,625 psychiatric inpatients.

Authors:  Olesya I Zorina; Patrick Haueis; Waldemar Greil; Renate Grohmann; Gerd A Kullak-Ublick; Stefan Russmann
Journal:  Drug Saf       Date:  2013-04       Impact factor: 5.606

10.  Adverse drug reactions: a retrospective review of hospitalized patients at a state psychiatric hospital.

Authors:  Courtney A Iuppa; Leigh Anne Nelson; Ellie Elliott; Roger W Sommi
Journal:  Hosp Pharm       Date:  2013-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.